Treatments: Follicular Thyroid Carcinoma
How follicular thyroid carcinoma is treated, from surgery through long-term follow-up.
CONDITIONS: FOLLICULAR THYROID CARCINOMA
This page covers how follicular thyroid carcinoma is treated. For background on what follicular thyroid carcinoma is, how it differs from other thyroid cancers, and how it is diagnosed, see the conditions page below.
SURGERY: THE MAIN TREATMENT
Surgery to remove the tumor is the foundation of treatment for follicular thyroid carcinoma. There are two main operations, and the choice depends on the tumor's size, features, and whether it has spread.
Lobectomy (removing half of the thyroid). For smaller tumors confined to one side, and for minimally invasive follicular carcinoma, removing only the affected lobe (along with the central bridge of tissue, the isthmus) is often enough. Lobectomy has fewer complications than removing the whole gland and often allows a person to keep making some of their own thyroid hormone.
Total thyroidectomy (removing the entire thyroid). Removing the whole gland is recommended for larger tumors (generally more than 4 cm), tumors that have grown outside the thyroid, tumors with extensive blood-vessel invasion, or cancer that has spread to lymph nodes or distant sites. It may also be chosen for tumors in both lobes or based on personal preference.
Because the final diagnosis often depends on the pathology report after surgery, some people first have a lobectomy and then, if the tissue shows a more invasive cancer, return for a second operation to remove the remaining thyroid (called a completion thyroidectomy). Removal of neck lymph nodes is generally reserved for people who have visible or biopsy-proven cancer in those nodes, since follicular thyroid carcinoma spreads to lymph nodes uncommonly.
RADIOACTIVE IODINE THERAPY
After a total thyroidectomy, some people receive radioactive iodine (RAI, also called I-131). Thyroid cells, including many thyroid cancer cells, naturally absorb iodine, so radioactive iodine can seek out and destroy any remaining thyroid tissue or cancer cells. RAI is used to eliminate leftover normal thyroid tissue, which makes follow-up blood tests more reliable, to treat suspected microscopic disease, and to treat cancer that has spread.
Radioactive iodine is not used for everyone. Its use is guided by the risk that the cancer will come back:
Not usually recommended for low-risk disease — for example, a small tumor (4 cm or less) confined to the thyroid, without blood-vessel invasion, and with reassuring blood tests after surgery. Research shows RAI does not reduce recurrence in low-risk cancer, so it is often avoided to prevent unnecessary side effects.
Selectively recommended for intermediate-risk features, such as a large tumor, limited blood-vessel invasion, or certain blood-test results after surgery. The decision is individualized.
Recommended for higher-risk disease, such as extensive blood-vessel invasion, cancer growing well beyond the thyroid, more aggressive tumor types, or known distant spread. In these situations, RAI can improve survival.
Radioactive iodine is generally well tolerated. Possible side effects include dry mouth, salivary gland swelling, changes in taste, and, with high total doses over time, a small increase in the risk of other cancers and temporary effects on fertility. Some tumors, particularly poorly differentiated ones, do not absorb iodine well; these are called "radioiodine-refractory" and are treated differently.
THYROID HORMONE (LEVOTHYROXINE) THERAPY
Anyone who has had the whole thyroid removed needs to take thyroid hormone (levothyroxine) every day for life, because the body can no longer make it. People who have had only a lobectomy sometimes need it as well, depending on how the remaining lobe functions.
Levothyroxine serves two purposes. First, it replaces the hormone the body needs to function normally. Second, it can be dosed to lower a pituitary hormone called TSH (thyroid-stimulating hormone). TSH can stimulate thyroid cancer cells to grow, so keeping it low may reduce the chance of the cancer returning in people at higher risk.
How low the TSH target should be depends on the individual:
People with known remaining cancer or a high risk of recurrence usually aim for a TSH kept below the normal range.
People who are free of disease and at low risk usually keep TSH within the normal range.
Targets are re-evaluated over time, and many people who remain cancer-free for several years shift to a normal-range goal.
Keeping TSH very low is a balancing act, because too much thyroid hormone (hyperthyroidism) can cause problems such as an irregular heartbeat (especially in older adults) and bone thinning (especially in postmenopausal women). For this reason, doses are personalized, and people on suppressive doses are often advised to get enough calcium and vitamin D.
FOLLOW-UP AND MONITORING
Follicular thyroid carcinoma can return years after treatment, so long-term follow-up is important. Most recurrences appear within the first several years, but late recurrences, though rare, are possible. Monitoring typically includes:
Physical examination of the neck.
Blood tests, including TSH and a tumor marker called thyroglobulin, along with thyroglobulin antibodies. In people who have had the whole thyroid removed, a rising thyroglobulin level can be an early sign that cancer has returned.
Neck ultrasound, usually starting 6 to 12 months after surgery and then as needed.
If blood tests or imaging suggest the cancer may have come back, additional imaging (such as CT, MRI, PET, or a radioactive iodine scan) and sometimes a biopsy are used to locate it. For people at low risk who remain free of cancer for many years, monitoring may eventually be scaled back or stopped.
TREATMENT OF RECURRENT OR ADVANCED DISEASE
If follicular thyroid carcinoma comes back or spreads, treatment is tailored to where the cancer is and how quickly it is growing:
Surgery to remove recurrent or isolated spread when it can be safely done.
Radioactive iodine for disease that still absorbs iodine.
Local treatments such as external-beam radiation, or techniques that destroy tumors directly, for example ethanol ablation, cryoablation, or radiofrequency ablation, for limited or symptomatic areas.
Systemic (whole-body) immunotherapy for cancer that is progressing and no longer responds to iodine. These include targeted pills called kinase inhibitors, such as lenvatinib and sorafenib. When cancer is tested and found to carry specific gene changes, drugs matched to those changes may be used. Clinical trials are also an option.
Careful observation is often appropriate when advanced disease is stable, slow-growing, and not causing symptoms, since starting medication too early has its own downsides.
SIDE EFFECTS TO KNOW
Treatment for follicular thyroid carcinoma can involve several possible side effects, depending on which treatments are used.
Surgery: Temporary or, less often, permanent hoarseness (from irritation or injury to a nerve near the thyroid) and temporary or permanent low calcium levels (from effects on the small parathyroid glands next to the thyroid) can occur.
Radioactive iodine: Temporary neck or salivary gland swelling and tenderness, dry mouth, altered taste, and temporary changes in fertility can occur; treatment planning generally accounts for these effects.
Thyroid hormone therapy: Life-long monitoring of thyroid hormone levels is needed, since a dose that is too high or too low can cause symptoms of its own.
KEY POINTS
Surgery is the main treatment; the extent depends on tumor size and features.
Radioactive iodine is used selectively, mainly for higher-risk disease.
Daily thyroid hormone is needed after total thyroidectomy, and its dose may be adjusted to keep TSH low based on risk.
Long-term monitoring with blood tests and ultrasound helps catch any recurrence early.
The overall outlook for follicular thyroid carcinoma is very good, particularly when it is found early and confined to the thyroid.
This page is for general education and does not replace individualized advice from a treating physician or care team.